D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients
Open Access
- 10 November 2005
- journal article
- Published by Springer Nature in Leukemia
- Vol. 19 (12) , 2332-2333
- https://doi.org/10.1038/sj.leu.2403993
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- The development of imatinib as a therapeutic agent for chronic myeloid leukemiaBlood, 2005
- A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitorBlood, 2005
- Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to ImatinibLeukemia, 2004
- Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec®) in vitro and in vivoBiochemical Pharmacology, 2003
- Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABLCell, 2003
- Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate–resistant Bcr-Abl kinasesBlood, 2003
- Roots of Clinical Resistance to STI-571 Cancer TherapyScience, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001